1. Introduction
===============

Various risk scores currently used to predict mortality in systolic heart failure (SHF) patients have proven to be too complex for routine clinical use.^\[[@R1]--[@R5]\]^ The variables used in previous risk models have been very numerous and heterogeneous. Examples include clinical status, therapy (pharmacological and devices), laboratory parameters, and even functional test outcomes, which can change during hospitalization and with the progression of the disease. Some risk models are highly complex and may require laborious data entry or even the use of an interactive program.^\[[@R1],[@R2],[@R4],[@R5]\]^ In patients with atrial fibrillation (AF), the most commonly used predictors of stroke scores are CHADS~2~ \[congestive heart failure (CHF), hypertension, age, diabetes, stroke (doubled)\], CHA~2~DS~2~-VASc \[CHF, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, Age 65--74, and sex category (female)\], and R~2~CHADS~2~ \[renal dysfunction (doubled), CHF, hypertension, age, diabetes, stroke (doubled)\]. These scores are easily calculated because they include common cardiovascular risk factors^\[[@R6]--[@R10]\]^ and have been extended for use in predicting endpoints other than stroke^\[[@R11]--[@R13]\]^ and even for use in patients without AF.^\[[@R14]--[@R17]\]^ Some studies have shown that they can also be used to predict all-cause mortality in heart failure (HF) patients.^\[[@R17],[@R18]\]^ However, their effectiveness for stratifying mortality risk in SHF patients with and without AF is unknown. Therefore, this study investigated the value of these risk scores for predicting all-cause mortality in patients with SHF.

2. Methods
==========

2.1. Study designs and patients
-------------------------------

The Taiwan Society of Cardiology---Heart Failure with reduced Ejection Fraction (TSOC-HFrEF) registry contains data obtained by a prospective, multicenter, observational survey of patients treated for HF at 21 medical centers in Taiwan. The inclusion criteria for the survey were age older than 18 years and hospitalization for either acute new-onset HF or acute decompensation of chronic HF with reduced left ventricular ejection fraction (LVEF). Enrolment criteria included LVEF less than 40% documented before enrollment by either echocardiography or left ventriculography during the index hospitalization. The only exclusion criterion was age less than 18 years old. The patients were consecutively enrolled at each participating site. Because this was an observational study, no specific protocol was established, and no recommendations for HF evaluation and management were made. Drug prescriptions, diagnostic tests, and therapeutic managements were left to the discretion of the attending cardiologists. Data were collected only after participating patients read the study information and gave written informed consent. Data collection for the index hospitalization included the period from the time of initial care to the time of discharge or death. Follow-up data were collected after 6 and 12 months. The design of this registry study was approved by the institutional review board (IRB) of each participating institution. Data were collected with a uniform case report form approved by the IRB of each medical center. After obtaining written informed consent to participate from each patient, the hospital investigator or research coordinator entered the patient data into an online database. Data collected from medical records included baseline characteristics, medical history, HF severity, echocardiographic data, in-hospital mortality, and discharge medications. The body mass index (BMI) and other echocardiographic data were also obtained. All other data were self-reported and confirmed by available medical records. The detailed study protocol is described in the previous report.^\[[@R19]\]^

2.2. Definition
---------------

Renal dysfunction and chronic kidney disease (CKD) were defined as an estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m^2^. The eGFR was calculated using the abbreviated Modification of the Diet in Renal Disease Study equation: eGFR (mL/min/1.73 m^2^) = 186.3 × (serum creatinine \[mg/dL\])^−1.154^× (age \[years\])^−0.203^× (0.742 in females).^\[[@R20]\]^ Alcoholism were defined as patients whose average daily wine consumption exceeded 300 mL or whose average daily liquor consumption exceeded 60 mL.

2.3. Statistical analysis
-------------------------

The statistical analyses included all enrolled patients. Descriptive summaries were presented for all patients and for all subgroups of patients. Quantitative data were expressed as means ±  standard deviation; categorical variables were reported as percentages. Student *t* test was used to compare continuous data, and *χ*^2^ test or Fisher exact test was used to compare categorical data. A multivariate analysis was performed with a logistic stepwise regression model to determine the independent predictors of 1-year mortality. The CHADS~2~, CHA~2~DS~2~-VASc, and R~2~CHADS~2~ scores were sequentially entered in 3 different models (CHADS~2~ in model 1, CHA~2~DS~2~-VASc in model 2, and R~2~CHADS~2~ in model 3) for multivariate analysis. All the variables in Table [1](#T1){ref-type="table"}, supplementary Table 1 and supplementary Table 2 with *P* value \< .05 in predicting mortality by univariate analysis were enrolled into multivariate analysis except those variables of the different scoring systems in different models. The accuracies of CHADS~2~, CHA~2~DS~2~-VASc, and R~2~CHADS~2~ scores for predicting all-cause mortality were calculated by c-indexes based on receiver operating characteristic (ROC) curves. Areas under the ROC curves for these 3 scoring systems were compared using DeLong test. The net reclassification index (NRI) was used to quantify the accuracy of the risk scoring system in classifying subjects, as compared with other risk-scoring systems when the DeLong test revealed differences in area under the ROC curves for the 3 scoring systems. A *P* value of \< .05 was considered statistically significant. The statistical analyses were performed using SAS statistical software Version 9.4 (SAS Institute, Cary, NC).
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Baseline characteristics of 1-year mortality group and 1-year survival group in 1311 SHF patients.
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3. Results
==========

3.1. Baseline characteristics and 1-year mortality in SHF patients
------------------------------------------------------------------

The TSOC-HFrEF registry contains data for 1509 patients treated in 21 medical centers from May, 2013 to October, 2014. Detailed baseline characteristics are presented in our previous registry report.^\[[@R19]\]^ The TSOC-HFrEF registry contains data for an observational survey with no specific protocol for intervention during follow-up. Patients were free to withdraw their consent and participation for any reason and at any time. During the first year, 198 (13.2%) patients were lost to follow-up. Therefore, 1311 (86.8%) patients were included in the final analysis. Of these, 354 (27%) patients had a history of AF rhythm. During the 1-year follow-up, 250 (19%) patients died. Table [1](#T1){ref-type="table"} compares SHF patients who died (mortality group) and SHF patients who survived (survival group) during the 1-year follow-up. The mortality group was characterized by significantly older age (68.7 ± 14.2 vs 62.0 ± 16.3 years, *P* \< .001), significantly lower BMI (23.9 ± 5.1 vs 25.6 ± 5.0, *P* \< .001), and significantly higher incidences of the following: diabetes mellitus (DM) (52.8% vs 42.1%, *P* = .002), coronary artery disease (CAD) (47.6% vs 40.7%, *P* = .047), CKD (47.6% vs 27.3%, *P* \< .001), peripheral artery occlusion disease (PAOD) (10.8% vs 5.7%, *P* = .004), chronic obstructive pulmonary disease (16% vs 9.3%, *P* = .002), thyroid disorder (8.4% vs 4%, *P* = .003) and previous valvular surgery (8% vs 4.1%, *P* = .009). Compared with the survival group, the mortality group also had significantly lower incidences of treatment with the following: beta-blocker, angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers (ACEI/ARB), diuretics and antiplatelet (all *P* \< .05). Finally, the mortality group had significantly higher scores for R~2~CHADS~2~, CHADS~2~, and CHA~2~DS~2~-VASc (3.4 ± 1.7 vs 2.8 ± 1.5, *P* \< .001; 2.5 ± 1.1 vs 2.2 ± 1.0, *P* = .002; 3.7 ± 1.6 vs 3.2 ± 1.6, respectively, *P* \< .001).

3.2. Multivariate analysis 1-year all-cause mortality predictors in SHF patients
--------------------------------------------------------------------------------

Multivariate analysis of all variables with *P* value less than.05 showed that BMI, thyroid disorder, and valvular surgery history were independent predictors of 1-year mortality in all 3 models (all *P* \< .05). CKD was a significant independent predictor of 1-year mortality in model 1 and model 2 (*P* \< .001). The CHADS~2~ score (odds ratio 1.148, 95% CI: 1.003--1.315, *P* = .045), CHA~2~DS~2~-VASc score (odds ratio 1.130, 95% CI: 1.031--1.239, *P* = .009), and R~2~CHADS~2~ score (odds ratio 1.282, 95% CI: 1.172--1.402, *P* \< .001) were independent predictors of 1-year mortality in the different models. Table [2](#T2){ref-type="table"} shows the results.
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Univariate and multivariate analysis of 1-year mortality in SHF patients.
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3.3. Baseline characteristics and 1-year mortality in total SHF patients with or without AF
-------------------------------------------------------------------------------------------

Table [3](#T3){ref-type="table"} lists the baseline characteristics, in-hospital mortality, and 1-year mortality in SHF patients with or without AF. Of 354 SHF patients with a history of AF, 82 (23%) patients died during the 1-year follow-up. Supplemental Table 1 compares the mortality group and the survival group. Briefly, the mortality group were significantly older than the survival group (71.9 ± 13.1 vs 67.6 ± 14.5 years, respectively, *P* = .011) and were significantly more likely to have DM, CKD, previous valvular surgery, and paroxysmal AF (all *P* \< .05). The survival group were also significantly more likely to receive treatment with beta-blocker, ACEI/ARB, and diuretics (all *P* \< .05). The mortality group had significantly higher scores compared with the survival group for CHADS~2~ (2.7 ± 1.1 vs 2.3 ± 1.1, respectively, *P* = .011), for CHA~2~DS~2~-VASc (4.1 ± 1.5 vs 3.4 ± 1.7, respectively, *P* = .001), and for R~2~CHADS~2~ (3.7 ± 1.7 vs 2.9 ± 1.6, respectively, *P* \< .001). Multivariate analysis in different models showed that valvular surgery history, CKD, CHADS~2~, CHA~2~DS~2~-VASc, and R~2~CHADS~2~ were independent predictors of 1-year mortality. Table [4](#T4){ref-type="table"} shows the statistical results. In patients who had SHF but not AF, 168 (17.6%) patients died during the 1-year follow-up. Supplemental Table 2 compares the mortality group and the survival group. Multivariate analysis in different models showed that independent predictors of 1-year morality were BMI, CKD, and R~2~CHADS~2~. Table [5](#T5){ref-type="table"} shows the statistical results. Comparisons of patients with and without CKD showed that the CKD group had more elderly people with low BMI. Supplemental Table 3 also shows that the CKD group had more patients with DM, CAD, PAOD, previous stroke, previous myocardial infarction, and previous hear failure admission.
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Baseline characteristics of SHF patients with and without AF.
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Univariate and multivariate analysis of 1-year mortality in SHF patients with AF.
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Univariate and multivariate analysis of 1 year mortality in SHF patients without AF.
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3.4. Comparisons of different scoring systems as predictors of 1-year mortality in SHF patients with or without AF
------------------------------------------------------------------------------------------------------------------

Figure [1](#F1){ref-type="fig"} compares 1-year mortality rates in SHF patients with or without AF. The figure shows that, regardless of AF, 1-year mortality in SHF patients had significant positive associations with CHADS~2~, CHA~2~DS~2~-VASc, and R~2~CHADS~2~ scores (all *P* \< .05). Figure [2](#F2){ref-type="fig"} compares the ROC curves for different risk scoring systems used to predict 1-year mortality. Figure [2](#F2){ref-type="fig"}A shows that, for predicting totally mortality in SHF patients, the c-indexes based on area under the curve (AUC) were 0.5595 for CHADS~2~, 0.5898 for CHA~2~DS~2~-VASc, and 0.6091for R~2~CHADS~2~. That is, the c-index for R~2~CHADS~2~ score was significantly higher than those for CHADS~2~ and CHA~2~DS~2~-VASc (DeLong test, *P* \< .0001). Additionally, the R~2~CHADS~2~ score had a significantly higher NRI in comparison with the CHADS~2~ score (+39.8%; 95% CI: 26.2%--53.3%; *P* \< .0001) and in comparisons with the CHA~2~DS~2~-VASc score (+20.5%; 95% CI: 6.8%--34.3%; *P* \< .0001). Figure [2](#F2){ref-type="fig"}B shows that, for predicting all-cause mortality in SHF patients with AF, the c-indexes based on AUC did not significantly differ (*P* = .1436 in DeLong test) among the 3 scoring systems (0.5878, 0.6055, and 0.6267 for CHADS~2~, CHA~2~DS~2~-VASc, and R~2~CHADS~2~, respectively). Figure [2](#F2){ref-type="fig"}C shows that, for predicting all-cause mortality in SHF patients without AF, the c-index based on AUC was significantly higher (DeLong test, *P* = .0003) for R~2~CHADS~2~ (0.5987) compared with CHADS~2~ (0.5409), and CHA~2~DS~2~-VASc (0.5740). Additionally, the R2CHADS2 score obtained a significantly higher NRI in comparison with CHADS2 (+39.4%; 95% CI: 22.9%--55.8%; *P* \< .0001) and in comparison with CHA2DS2-VASc (+27.0%; 95% CI: 10.6%--43.4%; *P* = .0015).

![A, One-year all-cause mortality rate among different CHADS~2~ scores in SHF patients with and without AF. SHF patients who had high CHADS~2~ scores had a high 1-year mortality rate regardless of AF or not (all *P* \< .05). AF = atrial fibrillation, CHADS2 = congestive heart failure, hypertension, age, diabetes, stroke (doubled), SHF = systolic heart failure, SR = sinus rhythm. B, One-year all-cause mortality rate among different CHA~2~DS~2~-VASc scores in SHF patients with and without AF. SHF patients who had high CHA~2~DS~2~-VASc scores had a high 1-year mortality rate regardless of AF or not (all *P* \< .05). AF = atrial fibrillation, CHA~2~DS~2~-VASc = congestive heart failure, hypertension, age ≥ 75 (doubled), diabetes, stroke (doubled), vascular disease, age 65--74, and sex category (female), SHF = systolic heart failure, SR = sinus rhythm. C, One-year all-cause mortality rate among different R~2~CHADS~2~ scores in SHF patients with and without AF. SHF patients who had high R~2~CHADS~2~ scores had a high 1-year mortality rate regardless of AF or not (all *P* \< .05). AF = atrial fibrillation, R~2~CHADS~2~ = renal dysfunction (doubled), congestive heart failure, hypertension, age, diabetes, stroke (doubled), SHF = systolic heart failure, SR = sinus rhythm.](medi-96-e8338-g006){#F1}

![A, The ROC curves for CHADS~2~, CHA~2~DS~2~-VASc, and R~2~CHADS~2~ scoring systems in predicting 1-year all-cause mortality in SHF patients. Based on AUCs for predicting all-cause mortality in SHF patients, CHADS~2~, CHA~2~DS~2~-VASc, and R~2~CHADS~2~ scoring systems had c-indices of 0.5595, 0.5898, and 0.6091, respectively (DeLong test, *P* \< .0001). AUC = area under the curve, CHADS~2~ = congestive heart failure, hypertension, age, diabetes, stroke (doubled), CHA~2~DS~2~-VASc = congestive heart failure, hypertension, age ≥ 75 (doubled), diabetes, stroke (doubled), vascular disease, age 65--74, and sex category (female), R~2~CHADS~2~ = renal dysfunction (doubled), congestive heart failure, hypertension, age, diabetes, stroke (doubled), ROC = receiver operating characteristic, SHF = systolic heart failure. B, The ROC curves of CHADS~2~, CHA~2~DS~2~-VASc, and R~2~CHADS~2~ scoring systems for predicting 1-year all-cause mortality in SHF patients with AF. Based on AUCs for predicting all-cause mortality in SHF patients with AF, the CHADS~2~, CHA~2~DS~2~-VASc, and R~2~CHADS~2~ scoring systems had c-indices of 0.5878, 0.6055, and 0.6267, respectively (DeLong test, *P* = .1436). AUC = area under the curve, CHADS~2~ = congestive heart failure, hypertension, age, diabetes, stroke (doubled), CHA~2~DS~2~-VASc = congestive heart failure, hypertension, age ≥ 75 (doubled), diabetes, stroke (doubled), vascular disease, age 65--74, and sex category (female), R~2~CHADS~2~ = renal dysfunction (doubled), congestive heart failure, hypertension, age, diabetes, stroke (doubled), ROC = receiver operating characteristic, SHF = systolic heart failure. C, The ROC curves for CHADS~2~, CHA~2~DS~2~-VASc, and R~2~CHADS~2~ scoring systems used to predict 1-year all-cause mortality in SHF patients without AF. Based on AUCs for predicting all-cause mortality in SHF patients without AF, the CHADS~2~, CHA~2~DS~2~-VASc, and R~2~CHADS~2~ scoring systems had c-indices of 0.5409, 0.5740, and 0.5987, respectively (DeLong test, *P* = .0003). AUC = area under the curve, CHADS~2~ = congestive heart failure, hypertension, age, diabetes, stroke (doubled), CHA~2~DS~2~-VASc = congestive heart failure, hypertension, age ≥ 75 (doubled), diabetes, stroke (doubled), vascular disease, age 65--74, and sex category (female), R~2~CHADS~2~ = renal dysfunction (doubled), congestive heart failure, hypertension, age, diabetes, stroke (doubled), ROC = receiver operating characteristic, SHF = systolic heart failure.](medi-96-e8338-g007){#F2}

4. Discussion
=============

This SHF cohort study had 3 major findings. First, all 3 scoring systems are moderately accurate mortality predictors in SHF patients with or without AF. Second, R~2~CHADS~2~ is the best all-cause mortality predictor in total SHF patients without AF. However, the predictive accuracy does not significantly differ in SHF patients with AF. Third, regardless of the risk factors included in each scoring system, CKD was the only independent predictor of 1-year all-cause mortality in SHF patients with or without AF.

Previous studies show that CHADS~2~ score predicts all-cause mortality in SHF patients who undergo cardiac resynchronization therapy.^\[[@R17]\]^ Lip et al reported that the CHA~2~DS~2~-VASc score was associated with all-cause mortality risk in patients with incidental HF with or without AF. However, the predictive accuracy was modest.^\[[@R18]\]^ Our study showed that, for predicting all-cause mortality in SHF, R~2~CHADS~2~ score is more accurate than CHADS~2~ and CHA~2~DS~2~-VASc. The CKD is an important component of the R~2~CHADS~2~ score. Our study suggested that advanced age, low BMI, and comorbidity of DM, CAD, and PAOD are mortality risk factors in CKD. Previous studies show that renal insufficiency is an independent predictor of all-cause mortality in patients with diastolic or systolic dysfunction, in ambulatory patients with congestive HF, in HF patients (symptomatic or asymptomatic) with left ventricle systolic dysfunction, and in female patients with HF with systolic preserved or depressed systolic function.^\[[@R21]--[@R24]\]^ Most (73%) of the HFrEF patients in our study were male, and most were middle aged. CKD, a major component of R~2~CHADS~2~ score, was an independent predictor of all-cause mortality. The findings of this study are generally consistent with the literature despite some differences in patient characteristics. However, no studies have compared the use of CHADS~2~, CHA~2~DS~2~-VASc, and R~2~CHADS~2~ scores for predicting all-cause mortality in SHF patients with or without AF. This cohort study showed that, for predicting all-cause mortality in SHF patients with AF, all 3 scores had moderate accuracy, and predictive accuracy did not significantly differ. However, R~2~CHADS~2~ was the best mortality predictor specifically in those without AF. This study also showed CKD is the only independent predictor of all-cause mortality in SHF patients with or without AF, even when the analysis includes CHADS~2~ or CHA~2~DS~2~-VASc scores. This study confirmed previous reports that BMI, thyroid disorder, and valvular surgery history are independent predictors of all-cause mortality in SHF patients.^\[[@R5],[@R25]--[@R27]\]^ In SHF patients without AF, the only 2 independent predictors of all-cause mortality were CKD and BMI whereas CHADS~2~ and CHA~2~DS~2~-VASc were not independent predictors of all-cause mortality. These data may explain why R~2~CHADS~2~ was the superior predictor, especially in SHF without AF. Notably, this study showed that, in addition to these 3 scores, another independent predictor of all-cause mortality in SHF with AF is valvular surgery, which is consistent with previous reports that valvular disease is an independent predictor of all-cause mortality in HF patients with newly diagnosed AF.^\[[@R25],[@R28]\]^ The TSOC-HFrEF registry only enrolled patients with reduced left ventricular function (\<40%).^\[[@R19]\]^ During hospitalization, 36.5% of patients used inotropic agents. The use of inotropic agents may explain why physicians did not prescribe ACEI/ARB or beta-blocker at discharge. Nevertheless, the results for the TSOC-HFrEF registry suggest that guideline-directed medical treatment was under-utilized. This study showed that physicians managing HF should implement an evidence-based practice algorithm to improve HF care quality. Nevertheless, this study showed that, compared with 2 other commonly used risk-scoring systems, R~2~CHADS~2~ score is a better predictor of 1-year all-cause mortality in HFrEF patients. The patients with high-risk scores had a high 1-year mortality rate. More aggressive therapeutic management and frequent clinical follow-up may be indicated for these patients.

4.1. Study limitations
----------------------

Some limitations of this study are noted. First, the treatment strategy and the achievement of therapeutic goal of these risk factors (e.g., glycated hemoglobin level in diabetic patients and blood pressure level in hypertensive patients) may influence the impact of these diseases on all-cause mortality. Further prospective studies should be conducted to identify if the treatment of these diseases may influence the outcome of HFrEF patients. Second, this study did not compare other scoring systems such as the MAGGIC HF survival risk score or the Seattle Heart Failure Model. Nevertheless, this prospective study was the first and largest study of HF in Taiwan. Further studies are needed to survey and stratify HF risk specifically in Asian populations. Third, the only exclusion criterion in this study was age less than 18 years old. The percentage of patients with cancer was quite low in this registry (2.9%), and the patients with cancer did not show significantly higher mortality (*P* = .249). Discharge medications, including anticoagulants for AF, were not considered in the mortality analysis to avoid selection bias in discharge medications between mortality and survival (e.g., those with pulmonary edema, shock status, active bleeding, or other severe comorbidities during hospitalization or follow-up may not have had an opportunity for treatment with HF medication or anticoagulants). Therefore, the impact of medications on mortality in this retrospective study of registry data would have been difficult or even impossible. Nevertheless, all these factors such as cancer status and medications might affect mortality in SHF patients. Further prospective studies are needed to address this issue. Fourth, our study only enrolled patients who had heart failure with reduced ejection fraction, 73% of whom were middle-aged (63 ± 16 years old) males. Compared with the cohorts in other heart failure registries and surveys which also included some patients with preserved ejection fraction, our cohort was younger and had a larger percentage of male patients.^\[[@R29]--[@R31]\]^ This difference may limit the generalizability of our findings and their applicability to other cohorts.

5. Conclusion
=============

The CHADS~2~, CHA~2~DS~2~-VASc, and R~2~CHADS~2~ scores are moderately accurate predictors of all-cause mortality in SHF patients with or without AF. However, only CKD and R~2~CHADS~2~ scores are independent predictors of 1-year all-cause mortality in SHF patients with or without AF. In terms of predicting all-cause mortality in SHF patients, R~2~CHADS~2~ is the best of the three scoring systems, especially in SHF patients without AF.
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